Extraordinary meeting of the Committee for Medicinal Products for Human Use (CHMP): 29 December 2020
Location: Virtual meeting
This extraordinary meeting is planned in the context of the evaluation of the COVID-19 vaccine BNT162b2 developed by BioNTech and Pfizer.
The aim of the meeting will be to conclude the evaluation, if this is not possible at the CHMP’s extraordinary meeting on 21 December.
The Committee for Medicinal Products for Human Use (CHMP) is the committee that is responsible for preparing the Agency's opinions on all questions concerning human medicines.